Reach Us +44-1202-068036
Conceptual Questions In Prophylactic Oncology, Creation Of A Preventive Anticancerogenic Vaccine | 8132
ISSN: 2153-0769

Metabolomics:Open Access
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Conceptual questions in prophylactic oncology, creation of a preventive anticancerogenic vaccine

International Conference and Exhibition on Metabolomics & Systems Biology

Levon Mkrtchyan

ScientificTracks Abstracts: J Comput Sci Syst Biol

DOI: 10.4172/0974-7230.S1.02

Nowadays the total deterioration of ecology provokes an increase of mutagen pressure on the genome. Furthermore, it contributes to the weakening of the mononuclear phagocyte system, maintaining the cellular homeostasis. It follows that the most promising strategy for the primary cancer prevention is a compensation of the attenuated antitumor tolerance of adults and elderly people. For this purpose we created the Embryonic Antitumor Modulator (EATM) comprising the pool of proteins and proteoglycans of normal embryonic genesis, which sensitize CD4 + , CD8, N К and phagocytes, thereby enhancing the lysis and elimination of mutant cells, permanently arising in adults and older persons. We defined this guideline as target cancer immunoprophylaxis. We have every reason to suppose, that annually injection of the EATM (0.002g) is absolutely harmless and effective way to increase the natural antitumor resistibility of human organism. The EATM has also adjuvant antirelapse and antimetastatic action after the radical removal or radiotherapeutic devitalization of tumour. It prolongs remission duration in chemotherapy patients too. It has been found that the EATM has signal transduction ability. It enhances the informative proteins? synthesis. This fact partially explains some sanitizing paraclinical effects of this biological preparation, in particular, at neurodegenerative pathology. The immunological tolerance to the malignizing cells depends on their covering by fibrin network. This is the second protection level of cancer cells assimilated to the thromb and banal general pathological process. That?s why it is necessary to identify the hyperfibrinogenemia in apparently healthy people with universal factor of thrombogenic as well as oncological risk.
Professor Levon N. Mkrtchyan completed his PhD from Yerevan State Medical University. He has been given a doctor?s degree at the age of 33 in Moscow, Russia. He is a President of Armenian Medical Sciences Academy, Foreign Member of Russian Academy of Medical Sciences, Member of Armenian Oncologists` Scientific Committee, Professor of Yerevan State Medical University and Head of Prion Laboratory in Preventive Centre of Most Dangerous Infections under Ministry of Health of Armenia. He has a number of awards and diplomas for his scientific progress. Prof. Mkrtchyan is the author of 325 scientific articles and theses, including 13 monographs.
Leave Your Message 24x7